Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Vemurafenib by F. Hoffmann-La Roche for Sarcomas: Likelihood of Approval
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Sarcomas. According to GlobalData, Phase...
Vemurafenib by F. Hoffmann-La Roche for Thyroid Cancer: Likelihood of Approval
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Thyroid Cancer. According to GlobalData,...
Vemurafenib by F. Hoffmann-La Roche for Neuroblastoma: Likelihood of Approval
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Neuroblastoma. According to GlobalData, Phase...
Vemurafenib by F. Hoffmann-La Roche for Craniopharyngioma: Likelihood of Approval
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Craniopharyngioma. According to GlobalData, Phase...
Vemurafenib by F. Hoffmann-La Roche for Pancreatic Cancer: Likelihood of Approval
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Pancreatic Cancer. According to GlobalData,...
Vemurafenib by F. Hoffmann-La Roche for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According...
Vemurafenib by F. Hoffmann-La Roche for Follicular Thyroid Cancer: Likelihood of Approval
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Follicular Thyroid Cancer. According to...